Menzel, M., Kirchner, M., Kluck, K., Ball, M., Beck, S., Allgäuer, M., . . . Christopoulos, P. (2024). Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors. The journal of pathology: clinical research, 10(2), . https://doi.org/10.1002/cjp2.354
Chicago-Zitierstil (17. Ausg.)Menzel, Michael, et al. "Genomic Heterogeneity at Baseline Is Associated with T790M Resistance Mutations in EGFR-mutated Lung Cancer Treated with the First-/second-generation Tyrosine Kinase Inhibitors." The Journal of Pathology: Clinical Research 10, no. 2 (2024). https://doi.org/10.1002/cjp2.354.
MLA-Zitierstil (9. Ausg.)Menzel, Michael, et al. "Genomic Heterogeneity at Baseline Is Associated with T790M Resistance Mutations in EGFR-mutated Lung Cancer Treated with the First-/second-generation Tyrosine Kinase Inhibitors." The Journal of Pathology: Clinical Research, vol. 10, no. 2, 2024, https://doi.org/10.1002/cjp2.354.